Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.

NCT Number	NCT05328024
Lead Sponsor	Centre Paul Strauss Collaborators: Centre National de la Recherche Scientifique, France, Institut National de la Santé Et de la Recherche Médicale, France
Conditions	Head and Neck Cancer
Enrollment	60 participants
Start Date	2023-08-25
Primary Completion	2029-08-25 (estimated)
Study Completion	2029-08-25 (estimated)
Updated on ClinicalTrials.gov	2026-06-05